Ipsen Biopharmaceuticals, Inc.
1 Main Street
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
522 articles with Ipsen Biopharmaceuticals, Inc.
Ipsen announced findings from a new U.S. healthcare database analysis to assess the current treatment patterns of adults living with spasticity in a real-life setting.
Ipsen, a global specialty biopharmaceutical group, announces the launch of an Employee Shareholding plan.
Ipsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance
Ipsen, a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2021:
European Commission Approves Cabometyx® in Combination With Opdivo® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma
Ipsen announced that the European Commission has approved Cabometyx® in combination with Bristol Myers Squibb’s Opdivo® for the first-line treatment of advanced renal cell carcinoma.
Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide)
A total of 9 abstracts presented at the 18th Annual European Neuroendocrine Tumor Society (ENETS) Conference showcasing new data across the patient pathway in neuroendocrine tumors
Ipsen Delivered Sales Growth and Margin Expansion in 2020 - Focused on Executing New Strategy and Delivering Financial Objectives in 2021
Solid full year 2020 results in a COVID-19 environment, with Group sales growth of 3.0%1 and Core Operating margin at 32.0%
1/25/2021With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
Ipsen announced the appointment of Gwenan White as Executive Vice President, Communications and Public Affairs, effective March 2021.
TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications
Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
Ipsen, a specialty-care focused biopharmaceutical group, will host a virtual Capital Markets Day to highlight the Group’s new strategic priorities with the aim of driving continued growth and bringing transformative medicines to patients.
Two European leaders in biopharma and integrative software are working together to advance drug discovery
Ipsen Delivers Sales Growth in the First Nine Months of 2020 Despite the Impact of COVID-19 and Confirms Its 2020 Full Year Guidance
Ipsen, a global specialty-driven biopharmaceutical group, announced sales for the third quarter of 2020.
Ipsen to Present 12 Abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress Taking Place Jointly With the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)1-13
Ipsen announced the presentation of 12 abstracts during the 11th World Congress for Neurorehabilitation, taking place virtually between 7-11 October 2020.1-13
Ipsen announced the appointment of Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, effective 1 October 2020.
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
Cabometyx® in combination with Opdivo® showed superior overall survival and doubled median progression-free survival and objective response rate versus sunitinib, and had a favorable safety profile
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months
Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs
Ipsen Showcases Commitment to Patient-centric Advances in Oncology With Record Number of Abstracts to Be Presented at ESMO 2020 Virtual Congress
17 abstracts1 to be shared, spanning a wide range of different cancer types, therapies and clinical study and real-world evidence designs
Ipsen to Present New Insights at ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP), Including Global Phase III MOVE Trial Results
Seven presentations represent Ipsen’s largest presence to date at ASBMR, the world’s leading scientific organization for bone health research
8/27/2020Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines.